For Cancer Treatment: C.A.R.E. RadioImmunotherapy protocol was developed to work in combination with standard and personalized cancer care. By adding a beneficial low-dose radiation session prior to the patient’s course of treatment, the patented, computer-modeled protocol activates an immune response that protects healthy cells and organs from the devastating side effects of cancer treatment toxicity. Combining immuno-oncology agents with C.A.R.E. RadioImmunotherapy unlocks additional efficacy gains.
Just like an immunization for Polio or any other disease, a “small dose” stimulates gene and protein modulation that protects healthy cells and sensitizes organs from “insults” to the cellular immune system.
For Neurological, Autoimmune & Inflammatory Diseases: Diseases such as Type 1 Diabetes, Rheumatoid Arthritis, Lupus, Hashimoto’s, Parkinsons, HIV, etc. are caused by a disruption (such as myelin destruction) or inflammation at a cellular level. Our DNA repair processes identify gene pathways and proteins that can be used to develop drug therapies and help expedite drug and immunotherapy development.
Comparison of the genetic state of the immune system before and after treatment builds a predictive model for personalizing medical treatment and providing a “fast-track” for drug development.
Proliferative diseases (e.g. cancer)
Inflammatory and Autoimmune Diseases:
The therapy can conceivably be utilized for any inflammatory or autoimmune diseases such as HIV, Type 1 Diabetes, Rheumatoid Arthritis, Lupus, and Hashimoto’s disease, to name a few, where cellular repair can stop disease progression.
The cellular repair response is also involved in repairing and restoring of myelin commonly impacted by demyelinating diseases of the peripheral nervous system. The ability to protect the myelin is pertinent to brain cancer treatment where multiple radiation sessions can cause severe myelin degeneration. Applications may also exist for Alzheimer’s and Parkinson’s diseases …Learn More About Immunotherapy
What is the research behind C.A.R.E. RadioImmunotherapy℠?
Dr. Richard Blankenbecler, a world-renowned professor of Theoretical Physics at Stanford University’s SLAC National Accelerator Laboratory, developed and patented the process to activate latent genes that can be utilized in cancer, neurological, autoimmune, and inflammatory diseases. His discoveries and patents are based on $250 million of research over 16 years, sponsored by the U.S. Department of Energy’s Office of Science, Low Dose Radiation Research program.
The D.O.E. research validates that low levels of radiation are not only safe, but beneficial to humans.
At low doses of radiation, all organisms have cellular repair and response mechanisms that can keep adverse health effects from occurring, something that has evolved as life evolved (PNAS 2011). Radiation Barrier was conceived when Dr. Blankenbecler applied this knowledge to solve untreated medical dilemmas.
Pre-clinical research has shown that C.A.R.E. RadioImmunotherapy (patented as CARE Pre-Dose Therapy) activates genes in the healthy tissue that perform cellular repair. It might seem counter-intuitive that any amount of radiation can be beneficial however, the patented C.A.R.E. RadioImmunotherapy has been proven to make healthy cells more resistant to subsequent cancer treatments that are toxic to healthy tissue, such as radiation and drug therapy …Read More About Our Research
How does it work?
C.A.R.E. RadioImmunotherapy modulates the genomic and proteomic response to “insults” at the cellular level caused by cancer treatment toxicity, neurological, autoimmune, or inflammatory diseases. The C.A.R.E. RadioImmunotherapy protocol is used in combination with standard or personalized disease treatment to produce the best possible outcomes.